Chronic hepatitis C virus ( HCV ) infection is still a very serious global public problem, and its prevalence has an increased tendency year by year. A combination therapy of pegylated interferon - alpha and ribavirin ( Peg - IFN/RBV ), as a current recommended standard of care for patients with chronic HCV infection, is limited by high cost, ineffectiveness in some patients, serious adverse reactions, and even viral resistance in clinical application. With the expected approval of the HCV NS3/4A protease inhibitors, new treatment strategies may soon be available for nonresponders. Therefore, there will be an important clinical significance for accurately predicting who are more likely to achieve sustained virological response ( SVR ) before initial treatment or during the prophase of treatment, which will not only contribute to individual treatment decision making, but also be important for optimizing the best treatment duration. In this paper, we review the progress of the clinical predictors for the current treatment of chronic hepatitis C, which mainly based on reference to an English relevant article published in 2010.%慢性丙型肝炎病毒(HCV)感染仍然是一个十分严重的全球公共卫生问题,并且其感染率有逐年上升的趋势.聚乙二醇干扰素联合利巴韦林(Peg-IFN/RBV)是当前慢性HCV感染推荐的标准治疗方案,由于其昂贵的治疗费用、严重的副作用以及一部分患者无效甚至病毒耐药而使得其在临床应用中受到一定的限制.随着新的治疗药物如HCV NS3/4A蛋白酶抑制剂的即将批准上市,新的治疗策略有可能很快用于治疗无应答的患者.因此,在初始治疗前或者在治疗早期能够准确地预测出哪些患者更有可能获得持续病毒学应答将具有重要的临床意义,这不但有利于个体化治疗决策的制定,而且有利于最佳治疗持续时间的优化.本文主要参照2010年公开发表的一篇相关英文文献,对目前慢性丙型肝炎治疗的临床预测因素研究进展进行综述.
展开▼
